Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,244,165 papers from all fields of science
Search
Sign In
Create Free Account
BCX1777
Known as:
BCX-1777
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
forodesine hydrochloride
Broader (1)
immucillin H
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2009
Review
2009
Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
T. Robak
,
A. Korycka
,
E. Lech-Maranda
,
P. Robak
Molecules
2009
Corpus ID: 634081
For the past few years more and more new cytotoxic agents active in the treatment of hematological malignancies have been…
Expand
Review
2008
Review
2008
Novel purine nucleoside analogues for hematological malignancies.
A. Korycka
,
E. Lech-Maranda
,
T. Robak
Recent patents on anti-cancer drug discovery
2008
Corpus ID: 25281422
Recently, the search for more effective and safer antineoplastic agents has led to synthesis and introduction into preclinical…
Expand
Review
2006
Review
2006
Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
T. Robak
,
E. Lech-Maranda
,
A. Korycka
,
E. Robak
Current medicinal chemistry
2006
Corpus ID: 26733555
The purine nucleoside analogs (PNA) form an important group of cytotoxic drugs active in the treatment of neoplastic and…
Expand
2006
2006
Forodesine IV (Bcx-1777) Is Clinically Active in Relapsed/Refractory T-Cell Leukemia: Results of a Phase II Study (Interim Report).
R. Furman
,
L. Gore
,
F. Ravandi
,
D. Hoelzer
2006
Corpus ID: 78771135
Background: Forodesine, a potent, rationally designed purine nucleoside phosphorylase inhibitor, has shown clinical activity in T…
Expand
2006
2006
Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.
M. Duvic
,
A. Forero-Torres
,
F. Foss
,
E. Olsen
,
Youn H. Kim
2006
Corpus ID: 78419246
Abstract Background: Forodesine is a potent, rationally designed purine nucleoside phosphorylase (PNP) inhibitor that is orally…
Expand
Highly Cited
2005
Highly Cited
2005
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
V. Gandhi
,
J. Kilpatrick
,
+9 authors
Deborah A. Thomas
Blood
2005
Corpus ID: 278201
The discovery of purine nucleoside phosphorylase (PNP) deficiency and T lymphocytopenia suggested that inhibition of this enzyme…
Expand
2004
2004
Intravenous Forodesine (BCX-1777), a Novel Purine Nucleoside Phosphorylase (PNP) Inhibitor, Demonstrates Clinical Activity in Patients with Refractory Cutaneous T-Cell Lymphoma.
M. Duvic
,
F. Foss
,
+4 authors
J. Kilpatrick
2004
Corpus ID: 78937426
The profound suppression of T-cell immunity seen in patients with an inherited PNP deficiency supports the potential application…
Expand
Highly Cited
2003
Highly Cited
2003
Mechanism of inhibition of T-acute lymphoblastic leukemia cells by PNP inhibitor--BCX-1777.
S. Bantia
,
S. Ananth
,
C. Parker
,
L. L. Horn
,
Ramanda Upshaw
International immunopharmacology
2003
Corpus ID: 45577292
2003
2003
Arsenate reduction in human erythrocytes and rats--testing the role of purine nucleoside phosphorylase.
B. Németi
,
I. Csanaky
,
Z. Gregus
Toxicological sciences : an official journal of…
2003
Corpus ID: 25415058
Reduction of the pentavalent arsenate (AsV) to the thiol-reactive arsenite (AsIII) toxifies this environmentally prevalent form…
Expand
Highly Cited
2001
Highly Cited
2001
Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)--a novel potent and orally active immunosuppressive agent.
S. Bantia
,
P. Miller
,
+7 authors
J. Sandhu
International immunopharmacology
2001
Corpus ID: 39841046
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE